Pharmapedia Pro
Back to News
Drug Safety9 Oct 2026Source: FDA Safety Alerts

Early Alert Issued for Philips Lumify Diagnostic Ultrasound System Issues

The US Food and Drug Administration has issued an early alert regarding a potentially high-risk device issue affecting the Philips Lumify diagnostic ultrasound system across multiple Android and iOS software versions. The problem involves a software glitch where the app may fail to recognize a registered transducer and demand unexpected re-registration, which requires a Wi-Fi or cellular signal. Additionally, unstable USB cable connections between the transducer and the compatible device can disrupt continuous functioning.

Philips Ultrasound notified affected customers to recommend specific precautionary measures to prevent scanning delays or loss of functionality. These measures include using the system only in areas with accessible cellular or Wi-Fi signals unless an immediate backup is present, keeping backup ultrasound devices available, and sharing the manufacturer letter with all device users. The manufacturer is currently developing a software update to resolve the registration issue and is investigating the cause of the connection failures.

Key points

  • Affected products include specific software versions of the Philips Lumify Diagnostic Ultrasound System on both Android and iOS platforms.
  • The software may prompt unexpected re-registration before point-of-care use, blocking scanning until connected to Wi-Fi or cellular data.
  • USB connections between the transducer and compatible tablets or phones may also disconnect or become unstable during use.
  • Reports associated with this issue include serious injuries and patient deaths, particularly in pre-hospital or remote environments.

What it means for you

Clinicians and healthcare facilities utilizing portable ultrasound systems should ensure backup devices are immediately available and restrict Lumify usage to areas with reliable network connectivity until the software update is released. Practitioners in Pakistan should check with local suppliers or the Drug Regulatory Authority of Pakistan to determine if these specific affected Lumify models are in local use and to receive further operational guidance.

Read the original announcement

Early Alert: Diagnostic Ultrasound System Issue from Philips Ultrasound

Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.